BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 25467143)

  • 1. The contrasting epigenetic role of RUNX3 when compared with that of MGMT and TIMP3 in glioblastoma multiforme clinical outcomes.
    Saraiva-Esperón U; Ruibal A; Herranz M
    J Neurol Sci; 2014 Dec; 347(1-2):325-31. PubMed ID: 25467143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
    Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
    Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only.
    De Schutter H; Geeraerts H; Verbeken E; Nuyts S
    Oncol Rep; 2009 Feb; 21(2):507-13. PubMed ID: 19148529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme.
    Oberstadt MC; Bien-Möller S; Weitmann K; Herzog S; Hentschel K; Rimmbach C; Vogelgesang S; Balz E; Fink M; Michael H; Zeden JP; Bruckmüller H; Werk AN; Cascorbi I; Hoffmann W; Rosskopf D; Schroeder HW; Kroemer HK
    BMC Cancer; 2013 Dec; 13():617. PubMed ID: 24380367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of apparent diffusion coefficient values measured by diffusion MRI and MGMT promoter methylation semiquantitatively analyzed with MS-MLPA in patients with glioblastoma multiforme.
    Sunwoo L; Choi SH; Park CK; Kim JW; Yi KS; Lee WJ; Yoon TJ; Song SW; Kim JE; Kim JY; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH; Chang KH
    J Magn Reson Imaging; 2013 Feb; 37(2):351-8. PubMed ID: 23023975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas.
    Yachi K; Watanabe T; Ohta T; Fukushima T; Yoshino A; Ogino A; Katayama Y; Nagase H
    Int J Oncol; 2008 Sep; 33(3):469-75. PubMed ID: 18695875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Clinical Implications of Inconsistently Methylated Results from Glioblastoma MGMT Testing by Replicate Methylation-Specific PCR.
    Xia D; Reardon DA; Bruce JL; Lindeman NI
    J Mol Diagn; 2016 Nov; 18(6):864-871. PubMed ID: 27639200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequent hypermethylation of the DNA repair gene MGMT in long-term survivors of glioblastoma multiforme.
    Martinez R; Schackert G; Yaya-Tur R; Rojas-Marcos I; Herman JG; Esteller M
    J Neurooncol; 2007 May; 83(1):91-3. PubMed ID: 17164975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of
    Brandes AA; Franceschi E; Paccapelo A; Tallini G; De Biase D; Ghimenton C; Danieli D; Zunarelli E; Lanza G; Silini EM; Sturiale C; Volpin L; Servadei F; Talacchi A; Fioravanti A; Pia Foschini M; Bartolini S; Pession A; Ermani M
    Oncologist; 2017 Apr; 22(4):432-437. PubMed ID: 28275120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognosis of glioblastoma with faint MGMT methylation-specific PCR product.
    Hsu CY; Ho HL; Lin SC; Chang-Chien YC; Chen MH; Hsu SP; Yen YS; Guo WY; Ho DM
    J Neurooncol; 2015 Mar; 122(1):179-88. PubMed ID: 25575938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin.
    Park CK; Park SH; Lee SH; Kim CY; Kim DW; Paek SH; Kim DG; Heo DS; Kim IH; Jung HW
    Neuropathology; 2009 Aug; 29(4):443-9. PubMed ID: 19170894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of the methylation status of MGMT in different regions within glioblastoma multiforme.
    Hamilton MG; Roldán G; Magliocco A; McIntyre JB; Parney I; Easaw JC
    J Neurooncol; 2011 Apr; 102(2):255-60. PubMed ID: 20652362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Prognostic Roles of Gender and O6-Methylguanine-DNA Methyltransferase Methylation Status in Glioblastoma Patients: The Female Power.
    Franceschi E; Tosoni A; Minichillo S; Depenni R; Paccapelo A; Bartolini S; Michiara M; Pavesi G; Urbini B; Crisi G; Cavallo MA; Tosatto L; Dazzi C; Biasini C; Pasini G; Balestrini D; Zanelli F; Ramponi V; Fioravanti A; Giombelli E; De Biase D; Baruzzi A; Brandes AA;
    World Neurosurg; 2018 Apr; 112():e342-e347. PubMed ID: 29337169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The significance of MGMT methylation in Glioblastoma Multiforme prognosis.
    Rao AM; Quddusi A; Shamim MS
    J Pak Med Assoc; 2018 Jul; 68(7):1137-1139. PubMed ID: 30317322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between MGMT promoter hypermethylation and p53 mutation in glioblastoma.
    Shamsara J; Sharif S; Afsharnezhad S; Lotfi M; Raziee HR; Ghaffarzadegan K; Moradi A; Rahighi S; Behravan J
    Cancer Invest; 2009 Oct; 27(8):825-9. PubMed ID: 19544111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A three-gene signature for prognosis in patients with MGMT promoter-methylated glioblastoma.
    Wang W; Zhang L; Wang Z; Yang F; Wang H; Liang T; Wu F; Lan Q; Wang J; Zhao J
    Oncotarget; 2016 Oct; 7(43):69991-69999. PubMed ID: 27588397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Status of O⁶ -methylguanine-DNA methyltransferase [MGMT] gene promoter methylation among patients with glioblastomas from India.
    Nehru GA; Pai R; Samuel P; Chacko AG; Chacko G
    Neurol India; 2012; 60(5):481-6. PubMed ID: 23135024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging.
    Drabycz S; Roldán G; de Robles P; Adler D; McIntyre JB; Magliocco AM; Cairncross JG; Mitchell JR
    Neuroimage; 2010 Jan; 49(2):1398-405. PubMed ID: 19796694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NDRG2 and NDRG4 Expression Is Altered in Glioblastoma and Influences Survival in Patients with MGMT-methylated Tumors.
    Kolodziej MA; Weischer C; Reinges MH; Uhl E; Weigand MA; Schwarm FP; Schänzer A; Acker T; Quint K; Uhle F; Stein M
    Anticancer Res; 2016 Mar; 36(3):887-97. PubMed ID: 26976975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas.
    Ellingson BM; Cloughesy TF; Pope WB; Zaw TM; Phillips H; Lalezari S; Nghiemphu PL; Ibrahim H; Naeini KM; Harris RJ; Lai A
    Neuroimage; 2012 Jan; 59(2):908-16. PubMed ID: 22001163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.